Impact of CD19 CAR T‐Cell Therapy on Pathogen‐Specific Antibody Titers in Lymphoma Patients
MeV, MuV, RuV, VZV, and tetanus toxoid IgG remained stable following CD19 CAR T-cell therapy, while pneumococcal and Hib IgG titers showed marginal quantitative declines, without any fourfold reductions. Overall, humoral immunity at Day 100 following CD19 CAR T-cell therapy remained largely preserved. These seroprevalence findings suggest that routine revaccination may not be required in our patient cohort and highlight the importance of patient monitoring to inform revaccination decisions.
Authors
- Elizabeth Groarke
- Derek G. Doherty (ORCID: https://orcid.org/0000-0002-4394-658X)
- Allison Waters (ORCID: https://orcid.org/0000-0002-5048-5021)
- Anthony M. McElligott (ORCID: https://orcid.org/0000-0003-3276-1341)
- C Armstrong
- Tor Hervig (ORCID: https://orcid.org/0000-0001-9441-253X)
- Des Crowley (ORCID: https://orcid.org/0000-0002-8491-9596)
- Nina Orfali (ORCID: https://orcid.org/0000-0001-7203-7580)
- Bacon Cl
- Elizabeth Higgins (ORCID: https://orcid.org/0000-0003-4123-4148)
- Elisabeth Vandenberghe (ORCID: https://orcid.org/0000-0002-7731-9437)
- N Y Gardiner
- Niall P Conlon
- Robert Henderson
- Ellen Walsh
- Hayley Foy-Stones
Institutions
- University College Dublin (IE)
- Trinity College (CA)
- Trinity College Dublin (IE)
- Irish Blood Transfusion Service (IE)
- St. James's Hospital (IE)
- University of Bergen (NO)
Publication Details
- Journal
- Transplant Infectious Disease
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1111/tid.70188
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00